Juniper Networks Chosen to Upgrade Virgin Media O2’s Core IP Backbone Network to 800G Readiness
23.1.2023 11:00:00 EET | Business Wire | Press release
Juniper Networks (NYSE: JNPR), a leader in secure, AI-driven networks, today announced that Virgin Media O2, one of the UK’s largest fixed and mobile service providers with approximately 50 million online media connections, successfully upgraded its IP core backbone network with Juniper – capable of supporting 800G. Virgin Media O2 is investing in sustainable infrastructure for the long term that can support sustained data growth and bandwidth demands. Its investment underpins the rapid introduction of revenue-generating services while delivering significantly-reduced power, cooling and space consumption and costs.
Consistently good user experience is a fundamental benchmark of success. As its 5G and network expansion continues, Virgin Media O2 turned to Juniper to build a network that is 400G-enabled and 800G-ready to create a near future-proofed digital foundation for its customers. Virgin Media O2 selected Juniper as the technology partner for this strategic upgrade for numerous reasons, including its previous track record as a key networking provider for more than ten years with Virgin Media and O2 before their joint venture in 2021. Another significant factor was Juniper’s ability to deliver compelling economics for Virgin Media O2. These include long-term investment protection through continuous custom silicon innovation by keeping pace with market demands, the planned use of automation tools to help reduce operational costs and a favorable Total Cost of Ownership (TCO) with a reduced energy consumption design.
News Highlights
- In the past year, Virgin Media O2 has seen 32 percent traffic growth on its mobile network, 16 percent growth in broadband data downloads and a peak traffic load of 22TB, underlining the need for increased data capacity and flexible scalability
- Virgin Media O2 has successfully migrated all core traffic in its six backbone locations across the UK with Juniper Networks PTX10008 Packet Transport Routers, which are purpose-built to deliver cloud-optimized network transformation at scale and with operational flexibility
- The modular PTX10008 routers deliver reduced resource consumption as a result of inherently-sustainable design features, including front-to-back cooling, flexible power supplies that can use either high- or low-power modes and high-density port capability that enables optimized throughput in a compact form factor
- Scalable, secure 400G capability is achieved through ultra-high port density, native inline MACSec encryption on all ports, coupled with the latest generation of ASIC innovation that powers a range of line cards
- PTX10008 routers support 400G coherent optical transceivers (400G ZR and ZR+) without any density loss today, and are 800G-capable with upgradeability to 800G in the future with silicon innovation and easily-exchanged line cards in the chassis
- Virgin Media O2’s infrastructure will be underpinned by Juniper’s single operating system, Junos® OS Evolved. This will provide ongoing continuity for streamlined operations.
Supporting Quotes
“Virgin Media O2’s stated ambition is to ‘upgrade the UK’, providing fast, seamless broadband access and mobile services to as many homes and businesses as possible. This calls for responsible, strategic innovation and investment to create an agile network infrastructure that can simultaneously scale in step with our business, be mindful of resource consumption and deliver an extended lifecycle that protects our investment. Juniper is a long-standing technology partner, so it is very reassuring that it has the same vision for sustainable growth, user experience and the fundamental importance of digital enablement in our communities and economy.”
- Jeanie York, Chief Technology Officer, Virgin Media O2
“Service providers face a complex set of technical and commercial challenges that can be contradictory, even intractable—and likely only to multiply in the future—without the right approach. Virgin Media O2 has chosen to leverage silicon, software and automation innovation from Juniper that can turn complexity on its head to deliver a simplified, more reliable and more sustainable network foundation for its business. This means the company can embrace and accelerate growth and service evolution, safe in the knowledge that its millions of users will continue to be able to enjoy the best digital experiences going forward, whatever demands the future may bring.”
- Raj Yavatkar, Chief Technology Officer, Juniper Networks
Additional Information
Juniper’s
Climate Change & Sustainability Pages
CEO Blog:
Juniper’s Carbon Neutral Pledge
CTO Blog:
Sustainable Networking – The Time is Now
Juniper’s 2022
Corporate Sustainability Report
About Juniper Networks
Juniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world’s greatest challenges of well-being, sustainability and equality. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on Twitter, LinkedIn and Facebook.
Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.
Statement of Product Direction
The information on this page may contain Juniper's development and plans for future products, features, or enhancements ("SOPD Information"). SOPD Information is subject to change at any time, without notice. Juniper provides no assurances, and assumes no responsibility, that future products, features, or enhancements will be introduced. In no event should any purchase decision be based upon reliance of timeframes or specifics outlined as part of SOPD Information, because Juniper may delay or never introduce the future products, features, or enhancements.
Any SOPD Information within, or referenced or obtained from, this website by any person does not give rise to any reliance claim, or any estoppel, against Juniper in connection with, or arising out of, any representations set forth in the SOPD Information. Juniper is not liable for any loss or damage (howsoever incurred) by any person in connection with, or arising out of, any representations set forth in the SOPD Information.
Category - Cloud & Service Provider
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230123005101/en/
Contact information
Media Relations:
Penny Still
Juniper Networks
+44 (0) 1372 385 692
pstill@juniper.net
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 12:52:00 EEST | Press release
The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not merely a wage dispute. It stems from deep structural concerns regarding the company’s ESG management, lack of operational autonomy, and passive labor relations. Primarily, the union highlighted unresolved corporate governance issues, including allegations concerning unfair labor practices and the unauthorized use of employee personal data, which were prominently reported by South Korea's major broadcaster, MBC, in November 2025. The union believes this crisis stems from management's failure to address r
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 12:00:00 EEST | Press release
The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that elevates high-performance riders and horses to their rightful place on the world stage. Built on merit, integrity, and excellence, the PJL brings together the world’s best athletes to compete for the biggest prize pot in the discipline’s history, helping to create a more resilient, long-term financial model for the sport. Represented by sixteen teams, the PJL will introduce an industry-first rider selection process from a pool of 250 of the world’s leading riders. World-class, immersive events will unfold across fourteen ic
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 12:00:00 EEST | Press release
Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkbj) for the treatment of spastic cerebral palsy (CP). On top of safety and tolerability, the study will evaluate improvements in daily functioning, quality of life, motor abilities, and neurodevelopmental measures of the Cenegermin-bkbj intranasal formulation. CP is the most common motor disability in childhood, caused by injury or changes during early brain development. The most prevalent form, spastic CP, leads to muscle stiffness and difficulty with movement.2 “Cerebral palsy is a devastating disease, and for patients and families there are still no proven treatments beyond supportive care,” said Marcello Allegretti, Chief Scientific Officer at Dompé. “With our emerging intranasal NGF p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
